HepaRegeniX reported that the first patient in the second pilot portion of its Phase 1b/2a trial completed 28 days of darizmetinib, an oral MKK4 inhibitor given at 250 mg twice daily before major liver resection for colorectal metastases, with no treatment-related serious adverse events to date. The compound is designed to stabilize hepatocytes and accelerate regeneration, with the pilot cohort of 10 patients expected to complete in the fourth quarter of 2026 ahead of a seamless transition to randomized Phase 2a.
Key Points
- Oral MKK4 inhibitor completed 28-day dosing without treatment-related serious adverse events
- Targets hepatocyte survival and regenerative capacity after major liver resection
- Seamless Phase 1b/2a design authorized by FDA, EMA, Israeli regulators
Longevity Analysis
The liver is one of the few human organs with substantial regenerative capacity, and pharmacologically amplifying that capacity would extend far beyond oncologic surgery into transplant failure, acute injury, and chronic hepatic disease. Because the liver anchors detoxification, metabolic throughput, and hormone clearance, preserving functional hepatocyte mass after injury protects a network of downstream functions rather than a single organ. A drug that makes regeneration faster and more reliable also shifts what counts as operable tissue, a practical expansion of therapeutic margin in patients who would otherwise be excluded.
Original published by Longevity.Technology.